메뉴 건너뛰기




Volumn 65, Issue 2, 2010, Pages 363-371

A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts

Author keywords

Breast cancer resistance protein; Camptothecin; CPT 11; Prodrug

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACETYLCHOLINESTERASE; BEVACIZUMAB; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CETUXIMAB; CH 0793076; CISPLATIN; DNA TOPOISOMERASE; IRINOTECAN; OXALIPLATIN; PRODRUG; TP 300; UNCLASSIFIED DRUG;

EID: 71349087273     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1042-5     Document Type: Article
Times cited : (14)

References (28)
  • 1
    • 33644746018 scopus 로고    scopus 로고
    • Role of pharmacogenetics in irinotecan therapy
    • DOI 10.1016/j.canlet.2005.04.040, PII S0304383505009298, Pharmacogenomics in Cancer Chemotherapy: Recent Advances in Drug Transporters and Genome Analysis
    • FA de Jong MJA de Jonge J Verweij RHJ Mathijssen 2006 Role of pharmacogenetics in irinotecan therapy Cancer Lett 234 90 106 10.1016/j.canlet.2005.04.040 16343744 (Pubitemid 43343943)
    • (2006) Cancer Letters , vol.234 , Issue.1 , pp. 90-106
    • De Jong, F.A.1    De Jonge, M.J.A.2    Verweij, J.3    Mathijssen, R.H.J.4
  • 2
    • 33745928751 scopus 로고    scopus 로고
    • Management of advanced colorectal cancer: State of the art
    • DOI 10.1038/sj.bjc.6603233, PII 6603233
    • M Saunders T Iveson 2006 Management of advanced colorectal cancer: state of the art Br J Cancer 95 131 138 10.1038/sj.bjc.6603233 1:CAS:528: DC%2BD28XmvFajsL4%3D 16835584 (Pubitemid 44050911)
    • (2006) British Journal of Cancer , vol.95 , Issue.2 , pp. 131-138
    • Saunders, M.1    Iveson, T.2
  • 3
    • 33749249529 scopus 로고    scopus 로고
    • Irinotecan in the treatment of colorectal cancer
    • DOI 10.1016/j.ctrv.2006.07.001, PII S0305737206001368
    • C Fuchs EP Mitchell PM Hoff 2006 Irinotecan in the treatment of colorectal cancer Cancer Treat Rev 32 491 503 10.1016/j.ctrv.2006.07.001 1:CAS:528:DC%2BD28XhtVajsrfO 16959432 (Pubitemid 44478737)
    • (2006) Cancer Treatment Reviews , vol.32 , Issue.7 , pp. 491-503
    • Fuchs, C.1    Mitchell, E.P.2    Hoff, P.M.3
  • 4
    • 27644502351 scopus 로고    scopus 로고
    • Topotecan as second-line therapy for ovarian cancer: Dosage versus toxicity
    • DOI 10.1634/theoncologist.10-9-695
    • M Markman 2005 Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity Oncologist 10 695 697 10.1634/theoncologist.10-9-695 1:CAS:528:DC%2BD2MXht1Cgs7fE 16249348 (Pubitemid 41567280)
    • (2005) Oncologist , vol.10 , Issue.9 , pp. 695-697
    • Markman, M.1
  • 5
    • 34347243879 scopus 로고    scopus 로고
    • Topotecan for the treatment of small-cell lung cancer
    • DOI 10.1586/14737140.7.6.795
    • SJ Nicum MER O'Brien 2007 Topotecan for the treatment of small-cell lung cancer Expert Rev Anticancer Ther 7 795 801 10.1586/14737140.7.6.795 1:CAS:528:DC%2BD2sXmtFOhtbo%3D 17555389 (Pubitemid 47007986)
    • (2007) Expert Review of Anticancer Therapy , vol.7 , Issue.6 , pp. 795-801
    • Nicum, S.J.1    O'Brien, M.E.R.2
  • 7
    • 0030958098 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
    • 1:CAS:528:DyaK2sXivVehs7s%3D 9193346
    • E Gupta R Mick J Ramirez X Wang TM Lestingi EE Vokes MJ Ratain 1997 Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients J Clin Oncol 15 1502 1510 1:CAS:528: DyaK2sXivVehs7s%3D 9193346
    • (1997) J Clin Oncol , vol.15 , pp. 1502-1510
    • Gupta, E.1    Mick, R.2    Ramirez, J.3    Wang, X.4    Lestingi, T.M.5    Vokes, E.E.6    Ratain, M.J.7
  • 8
    • 3042677708 scopus 로고    scopus 로고
    • Flat-fixed dosing of irinotecan: Influence on pharmacokinetic and pharmacodynamic variability
    • DOI 10.1158/1078-0432.CCR-03-0591
    • FA de Jong RHJ Mathijssen R Xie J Verweij A Sparreboom 2004 Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability Clin Cancer Res 10 4068 4071 10.1158/1078-0432.CCR-03-0591 15217940 (Pubitemid 38812483)
    • (2004) Clinical Cancer Research , vol.10 , pp. 4068-4071
    • De Jong, F.A.1    Mathijssen, R.H.J.2    Xie, R.3    Verweij, J.4    Sparreboom, A.5
  • 9
    • 0032130703 scopus 로고    scopus 로고
    • Gastrointestinal toxicity or irinotecan
    • 1:STN:280:DyaK1czpsVWmuw%3D%3D 9726096
    • JR Hecht 1998 Gastrointestinal toxicity or irinotecan Oncology 12 72 78 1:STN:280:DyaK1czpsVWmuw%3D%3D 9726096
    • (1998) Oncology , vol.12 , pp. 72-78
    • Hecht, J.R.1
  • 10
    • 0032731703 scopus 로고    scopus 로고
    • The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11)
    • 1:CAS:528:DyaK1MXns1yhuro%3D 10570064
    • HM Dodds LP Rivory 1999 The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11) Mol Pharmacol 56 1346 1353 1:CAS:528:DyaK1MXns1yhuro%3D 10570064
    • (1999) Mol Pharmacol , vol.56 , pp. 1346-1353
    • Dodds, H.M.1    Rivory, L.P.2
  • 11
    • 0031661579 scopus 로고    scopus 로고
    • UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
    • DOI 10.1023/A:1008438109725
    • Y Ando H Saka G Asai S Sugiura K Shimokata T Kamataki 1998 UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan Ann Oncol 9 845 847 10.1023/A:1008438109725 1:STN:280:DyaK1M%2Fgs1Sgtw%3D%3D 9789606 (Pubitemid 28440442)
    • (1998) Annals of Oncology , vol.9 , Issue.8 , pp. 845-847
    • Ando, Y.1    Saka, H.2    Asai, G.3    Sugiura, S.4    Shimokata, K.5    Kamataki, T.6
  • 12
    • 0032934383 scopus 로고    scopus 로고
    • Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
    • DOI 10.1016/S0009-9236(99)70078-0
    • L Iyer D Hall S Das MA Mortell J Ramírez S Kim AD Rienzo MJ Ratain 1999 Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism Clin Pharmacol Ther 65 576 582 10.1016/S0009-9236(99) 70078-0 1:CAS:528:DyaK1MXjslSrt74%3D 10340924 (Pubitemid 29237332)
    • (1999) Clinical Pharmacology and Therapeutics , vol.65 , Issue.5 , pp. 576-582
    • Iyer, L.1    Hall, D.2    Das, S.3    Mortell, M.A.4    Ramirez, J.5    Kim, S.6    Di Rienzo, A.7    Ratain, M.J.8
  • 13
    • 0036148810 scopus 로고    scopus 로고
    • Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan
    • DOI 10.1097/00007691-200202000-00018
    • Y Ando H Ueoka T Sugiyama M Ichiki K Shimokata Y Hasegawa 2002 Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan Ther Drug Monit 24 111 116 10.1097/00007691-200202000-00018 1:CAS:528: DC%2BD38XhsVOitLg%3D 11805731 (Pubitemid 34106739)
    • (2002) Therapeutic Drug Monitoring , vol.24 , Issue.1 , pp. 111-116
    • Ando, Y.1    Ueoka, H.2    Sugiyama, T.3    Ichiki, M.4    Shimokata, K.5    Hasegawa, Y.6
  • 16
    • 4344632633 scopus 로고    scopus 로고
    • UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
    • 1:CAS:528:DC%2BD2cXmsVCgtr0%3D 15280927
    • E Marcuello A Altés A Menoyo E del Rio M Gómez-Pardo M Baiget 2004 UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer Br J Cancer 91 678 682 1:CAS:528: DC%2BD2cXmsVCgtr0%3D 15280927
    • (2004) Br J Cancer , vol.91 , pp. 678-682
    • Marcuello, E.1    Altés, A.2    Menoyo, A.3    Del Rio, E.4    Gómez-Pardo, M.5    Baiget, M.6
  • 18
  • 20
    • 33750552551 scopus 로고    scopus 로고
    • Mechanisms of cellular resistance to camptothecins
    • DOI 10.2174/092986706778773121
    • GL Beretta P Perego F Zunino 2006 Mechanisms of cellular resistance to camptothecins Curr Med Chem 13 3291 3305 10.2174/092986706778773121 1:CAS:528:DC%2BD28XhtFyrtr%2FF 17168852 (Pubitemid 44669776)
    • (2006) Current Medicinal Chemistry , vol.13 , Issue.27 , pp. 3291-3305
    • Beretta, G.L.1    Perego, P.2    Zunino, F.3
  • 21
    • 0034666736 scopus 로고    scopus 로고
    • BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells
    • DOI 10.1016/S0006-2952(00)00396-8, PII S0006295200003968
    • CH Yang E Schneider ML Kuo EL Volk E Rocchi YC Chen 2000 BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells Biochem Pharmacol 60 831 837 10.1016/S0006-2952(00)00396-8 1:CAS:528:DC%2BD3cXltlWgtL4%3D 10930538 (Pubitemid 30621668)
    • (2000) Biochemical Pharmacology , vol.60 , Issue.6 , pp. 831-837
    • Yang, C.-H.1    Schneider, E.2    Kuo, M.-L.3    Volk, E.L.4    Rocchi, E.5    Chen, Y.-C.6
  • 23
    • 0037050736 scopus 로고    scopus 로고
    • Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization
    • DOI 10.1002/ijc.10100
    • K Kage S Tsukahara T Sugiyama S Asada E Ishikawa T Tsuruo Y Sugimoto 2002 Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization Int J Cancer 97 626 630 10.1002/ijc.10100 1:CAS:528:DC%2BD38XpsFWjtA%3D%3D 11807788 (Pubitemid 34087801)
    • (2002) International Journal of Cancer , vol.97 , Issue.5 , pp. 626-630
    • Kage, K.1    Tsukahara, S.2    Sugiyama, T.3    Asada, S.4    Ishikawa, E.5    Tsuruo, T.6    Sugimoto, Y.7
  • 24
    • 0036772386 scopus 로고    scopus 로고
    • Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material
    • DOI 10.1002/path.1203
    • JE Diestra GL Scheffer I Català M Maliepaard JHM Schellens RJ Scheper JR Germà-Lluch MA Izquierdo 2002 Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material J Pathol 198 213 219 10.1002/path.1203 1:CAS:528:DC%2BD3sXivV2jsrY%3D 12237881 (Pubitemid 35243879)
    • (2002) Journal of Pathology , vol.198 , Issue.2 , pp. 213-219
    • Diestra, J.E.1    Scheffer, G.L.2    Catala, I.3    Maliepaard, M.4    Schellens, J.H.M.5    Scheper, R.J.6    Germa-Lluch, J.R.7    Izquierdo, M.A.8
  • 26
    • 39749119942 scopus 로고    scopus 로고
    • Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
    • DOI 10.1016/j.bcp.2007.10.016, PII S0006295207006946
    • BA Teicher 2008 Next generation topoisomerase I inhibitors: rationale and biomarker strategies Biochem Pharmacol 75 1262 1271 10.1016/j.bcp.2007.10.016 1:CAS:528:DC%2BD1cXislamtL8%3D 18061144 (Pubitemid 351305209)
    • (2008) Biochemical Pharmacology , vol.75 , Issue.6 , pp. 1262-1271
    • Teicher, B.A.1
  • 28
    • 0036163796 scopus 로고    scopus 로고
    • ABC Transporters as phenotypic markers and functional regulators of stem cells
    • 10.1634/stemcells.20-3-274 1:CAS:528:DC%2BD38XhtlGktbs%3D 11796918
    • KD Bunting 2002 ABC Transporters as phenotypic markers and functional regulators of stem cells Stem Cells 20 11 20 10.1634/stemcells.20-3-274 1:CAS:528:DC%2BD38XhtlGktbs%3D 11796918
    • (2002) Stem Cells , vol.20 , pp. 11-20
    • Bunting, K.D.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.